Stocks · News reference

Beam Therapeutics shares are trading higher after HC Wainwright & Co. reiterated its Buy rating on the stock and maintained a $80 price target.

Aug 25, 2026, 5:20 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncAug 31, 2026, 11:00 AMNa
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
Beam Therapeutics announced management participation in three major investor conferences in September 2026. The company also reported progress on its BEAM-302 trial in Alpha-1 Antitrypsin Deficiency, with dosing completed for adult and adolescent patients and updated data selected for presentation at the European Respiratory Society Congress 2026.
BEAM
BenzingaAug 25, 2026, 11:19 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.
BEAM
BenzingaAug 4, 2026, 11:14 AMBenzinga Newsdesk
Beam Therapeutics Q2 EPS $(1.18) Misses $(1.11) Estimate, Sales $490.000K Miss $16.370M Estimate
Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.11) by 6.31 percent. This is a 18 percent decrease over losses of $(1.00) per share from
BEAM